Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, September 16 at 2:00 PM EDT

Register Free →
logo
Get CLEATUS

Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases

Active
Grant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Department of Health and Human Services, is issuing a forecast for the Exploratory Clinical Trials Grants Program. This initiative aims to support short-term interventional studies, ranging from proof-of-concept and first-in-human trials to Phase I and Phase II clinical trials. The primary objective is to foster research that leads to clinically meaningful improvements in the prevention, diagnosis, and treatment of rheumatic, musculoskeletal, and skin conditions. Priority is given to studies that translate laboratory and preclinical research into clinical practice. Eligible research areas include dose-finding and safety studies for drugs, biologics, devices, or behavioral interventions, as well as trials focused on rare diseases and the predictive value of biomarkers. These grants are intended to provide the necessary data to support future, more robust clinical trials aimed at establishing the safety and efficacy of medical interventions.

General Info

NIAMS funding supports early-phase clinical trials advancing treatment of arthritis and musculoskeletal diseases.

Agency

Department Of Health And Human Services → National Institutes Of HealthView Agency

NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)View NAICS

Place of Performance

Not specified

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

Posted

forecast

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health
Contacts1 person available
OfficeUSA
Organization / Agency
Department Of Health And Human Services → National Institutes Of Health
View Agency Profile
Office AddressUSA
Contacts
National Institute of Arthritis and Musculoskeletal and Skin Diseases
contact@example.gov

Full Description

Show more

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications for Exploratory Clinical Trials Grants Program in the mission areas of NIAMS. The goal of the NIAMS clinical trial program is to support research leading to the prevention or reduction of symptoms and improve outcomes and function in patients with rheumatic, musculoskeletal, or skin conditions or diseases. The purpose of the Exploratory Clinical Trials Grants Program is to foster clinical trials that will lead to clinically meaningful improvements in prevention, diagnosis, or treatment of these conditions or diseases.

This Exploratory Clinical Trials Grants Program is designed to facilitate the execution of short-term, interventional studies. The Program is intended to support a range of exploratory studies, from proof-of-concept/first in human to Phase I and Phase II clinical trials. Such studies must meet the NIH definition of a clinical trial and be feasible within the time and budget constraints of this NOFO. A high priority is the use of such studies to stimulate the translation of promising research developments from laboratory, preclinical, and early human testing into clinical practice.

Examples of research areas of interest include, but are not limited to:

  • Conducting early-stage clinical trials, such as but not limited to; first in human, dose-finding or escalation/tolerability/safety/efficacy studies with drugs, biologics, devices, behavioral interventions, and/or physical therapy for treatment of arthritis, musculoskeletal, or skin conditions or diseases.
  • Clinical trials to provide data required to support a future, more robust clinical trial whose aim is to help establish the safety and efficacy or effectiveness of an intervention.
  • Clinical trials in rare diseases where the number of potential study participants is limited.
  • Clinical trials to determine the predictive value of a potential biomarker. 

Similar Contracts

Same NAICS industry code

NAICS: 541715
New
Federal
Specialized HPC Support (AI/ML & Quantum)
W2R2 USA Engr R & D Ctr

POSTED

about 2 hours ago

DEADLINE

in 5 days
View Details
NAICS: 541715
New
Federal
Transverse Distribution & Noise Analysis (COL-IRR)
Brookhaven National Labor -Doe Contractor

POSTED

1 day ago

DEADLINE

in 6 days
View Details
NAICS: 541715
New
Federal
High-Frequency RF System Simulation (COL-HSR)
Brookhaven National Labor -Doe Contractor

POSTED

1 day ago

DEADLINE

in 6 days
View Details
NAICS: 541715
New
Federal
RF System Power & Transient Analysis (COL-ESR)
Brookhaven National Labor -Doe Contractor

POSTED

1 day ago

DEADLINE

in 6 days
View Details
NAICS: 541715
New
Federal
In Situ Cryo-Electron Tomography (Cryo-ET) Imaging
National Institutes Of Health Olao

POSTED

1 day ago

DEADLINE

in 6 days
View Details
NAICS: 541715
New
Federal
Cryogenic Focused Ion Beam (Cryo-FIB) Milling
National Institutes Of Health Olao

POSTED

1 day ago

DEADLINE

in 6 days
View Details
NAICS: 541715
New
Federal
Correlative Light and Electron Microscopy (CLEM) Services
National Institutes Of Health Olao

POSTED

1 day ago

DEADLINE

in 6 days
View Details
NAICS: 541715
New
Federal
Emergent Drug Panel-Version 2 (EDP-V2) Kit
Solicitation # 000HCNBG-2026-99823
The Centers for Disease Control and Prevention intends to award a sole source firm fixed price contract to Cayman Chemical Company, Inc. for the design, manufacture, and distribution of the Emergent Drug Panel-Version 2 (EDP-V2) Kit. This initiative is part of the Traceable Opioid Material program and focuses on providing reference materials for emerging synthetic opioids and other novel psychoactive substances to approved laboratories. The anticipated period of performance runs from September 30, 2026, through September 29, 2027, with four additional option years for continued production and distribution. The selected contractor is responsible for ensuring all materials meet Current Good Manufacturing Practice standards and maintaining the necessary DEA registrations for the distribution of controlled substances. Key deliverables include providing technical support to recipient laboratories, conducting stability testing for shelf-life extensions on existing materials, and reporting distribution and use-case metrics to the CDC. This procurement is being conducted under the authority of FAR 12.102(a) to address the critical need for standardized reference materials in combating the opioid epidemic.
CDC Office Of Acquisition Services

POSTED

1 day ago

DEADLINE

in 4 days
View Details
NAICS: 541715
New
Federal
U.S. Army Contracting Command – Watervliet Arsenal (ACC-WVA) Organic Industrial Base (OIB) Modernization Commercial Solutions Opening (CSO)
Solicitation # W911PT26SC001
The U.S. Army Contracting Command – Watervliet Arsenal (ACC-WVA) is utilizing a Commercial Solutions Opening (CSO) under solicitation W911PT26SC001 to modernize its Organic Industrial Base. This competitive process, authorized by the National Defense Authorization Act for Fiscal Year 2026 and DFARS Subpart 212.70, seeks innovative commercial products, technologies, and services to implement convergent manufacturing. The goal is to integrate agile facilities, connected digital enterprises, and automation to enhance the delivery of materiel solutions to soldiers. The CSO is continuously open until September 30, 2027, and targets both traditional and non-traditional business entities. The acquisition process is structured in three phases: the submission of a written solution brief, an optional presentation or pitch, and a final request for a Commercial Solution Proposal. Awards will be made as fixed-price contracts under FAR Part 12 Commercial Item Procedures. Specific Areas of Interest (AoIs) have been published to address critical needs, including the conversion of a chromium plating facility, the installation of a FIPS 201-compliant Electronic Access Control System at Benet Laboratories, electrical infrastructure improvements at Building 120, and the procurement of advanced test inspection equipment and automated manufacturing solutions for cannon components. Eligible respondents must maintain an active registration in the System for Award Management (SAM) and possess a Unique Entity ID. While foreign-owned businesses may participate, all submissions must remain unclassified. Performance periods are generally limited to 12 months unless otherwise specified in an AoI. Evaluation is based on responsiveness to the AoI, technical merit, and price reasonableness, with final invoicing processed through the Wide Area Work Flow (WAWF) system.
W6QK Acc Wva

POSTED

1 day ago

DEADLINE

in about 1 year
View Details
NAICS: 541715
New
Federal
TTO Office-Wide Solicitation Proposers Day
Solicitation # DARPA-SN-26-105
The Defense Advanced Research Projects Agency is hosting a Proposers Day to support the TTO Office-Wide Solicitation, DARPA-PS-26-123. This initiative aims to redefine warfare by accelerating the development of advanced platforms and weapons designed to provide the United States with overwhelming advantages and a velocity of innovation that surpasses adversary capabilities. This special notice, identified by solicitation number DARPA-SN-26-105, was posted on September 9, 2026, with a response deadline of September 29, 2026. The effort falls under NAICS code 541715 and is managed by the TTO office located in Arlington, Virginia. Potential proposers are encouraged to review the primary solicitation on SAM.gov for specific research areas of interest.
Defense Advanced Research Projects Agcy

POSTED

1 day ago

DEADLINE

in 19 days
View Details
NAICS: 541715
New
Federal
Illumina DRAGEN Tier 3 Throughput License and v4 Server
Solicitation # 75N98026Q01167
The National Institutes of Health Nlm is seeking to procure an Illumina DRAGEN Tier 3 Throughput License and a v4 Server under solicitation 75N98026Q01167. This acquisition is critical for the NHGRI Undiagnosed Diseases Program to maintain high performance secondary analysis of next generation sequencing data for patients with rare diseases. The upgrade is necessary because the existing 2017 server has reached its end of support, lacks current security updates for its operating system, and possesses outdated hardware that cannot support modern pangenome references or improved variant calling workflows. The contract is categorized under NAICS code 541715 and is managed by the Department of Health and Human Services. The primary objective is to ensure compliance with NIH IT security requirements and prevent analysis delays by upgrading computational capacity and analytical accuracy. The place of performance is located in Bethesda, Maryland, with a response deadline of September 11, 2026.
National Institutes Of Health Nlm

POSTED

1 day ago

DEADLINE

in 1 day
View Details
NAICS: 541715
New
Federal
Neutron Strategic Technology Advanced Research (Neutron-STAR) Advanced Research Announcement (ARA)
Solicitation # FA9453-23-R-A004
The Neutron Strategic Technology Advanced Research (Neutron STAR) Advanced Research Announcement (ARA), solicitation FA9453-23-R-A004, is an open call by the Air Force Research Laboratory (AFRL) Geo Space Division for innovative research and development to enhance national nuclear deterrence operations. Operating under the authority of 10 U.S.C. 4023 for experimental purposes, the program seeks white papers and proposals across five key technical areas: nuclear system development, nuclear systems integration, nuclear system flight experimentation and evaluation, nuclear explosion monitoring, and nuclear command, control, and communication. The acquisition utilizes a hybrid approach, combining an open request for white papers with individual one-step or two-step solicitations. Awards may be issued through various instruments, including FAR-based contracts, Other Transaction (OT) agreements, or assistance instruments such as grants and cooperative agreements. The solicitation process typically follows a two-step procedure where unclassified white papers and Rough Order of Magnitude (ROM) cost estimates are evaluated for technical merit and value before full proposals are requested. Evaluation is based on a best-value determination, focusing on scientific soundness and relevance to mission needs. Key requirements for offerors include registration in the System for Award Management (SAM), submission of a Security Program Questionnaire, and certification of current and pending support for key personnel. The program maintains an unrestricted ceiling for the overarching announcement, with individual awards determined by funding availability and proposal quality. Administrative support is provided by designated contractors, and prospective offerors are encouraged to maintain dialogue with government representatives throughout the process.
FA9453 Afrl Rvk

POSTED

1 day ago

DEADLINE

in about 1 year
View Details

More opportunities from Department Of Health And Human Services → National Institutes Of Health

Same awarding agency

NAICS: 923120
New
Grant
Limited Competition: John Lewis NIMHD Research Endowment Program (S21 Clinical Trial Not Allowed)The John Lewis NIMHD Research Endowment Program, administered by the National Institutes of Health under the Department of Health and Human Services, is designed to enhance research infrastructure and training capacity at eligible institutions of higher education to support health disparities research. The program focuses on four strategic objectives: upgrading physical infrastructure and equipment, developing technical expertise, expanding relevant academic science programs, and recruiting high-level researchers for faculty positions. It is important to note that this program provides institutional support and does not directly fund specific research projects. This opportunity is a forecast for a limited competition, meaning only eligible organizations will be invited to apply. Applications will undergo a standard NIH peer-review process, and funding will be awarded based on the merit of the proposal. Clinical trials are not allowed under this specific program.
Administration of Public Health Programs

POSTED

2 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
NIH Director's Pioneer Award (DP1 Clinical Trial Optional)The NIH Director's Pioneer Award, managed by the National Institutes of Health under the Department of Health and Human Services, is a forecast opportunity designed to support exceptionally creative scientists. This award is part of the NIH Common Fund's High-Risk, High-Reward Research Program and targets bold, innovative research that has the potential to transform scientific areas relevant to the NIH mission. To qualify, proposed projects must explore new scientific directions that differ significantly from the investigator's previous work and existing research in the field. Applications are accepted across all scientific areas relevant to the NIH, and clinical trials are optional for this award. The program is intended for investigators pursuing high-risk research that could lead to major breakthroughs. Interested parties can contact the NIH Director's Pioneer Award Program for further details via the provided email contact.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

7 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
NIH Director's Early Independence Award (DP5 Clinical Trial Optional)The NIH Director's Early Independence Award, administered by the National Institutes of Health under the Department of Health and Human Services, is designed to accelerate the transition of outstanding early-career investigators into independent research roles. This award targets individuals who have recently completed their doctoral degrees or post-graduate clinical training and wish to bypass the traditional postdoctoral path. As part of the NIH Common Fund's High-Risk, High-Reward Research Program, the award is open to applications across all scientific fields that align with the NIH mission. This specific opportunity is listed as a forecast with the title NIH Director's Early Independence Award (DP5 Clinical Trial Optional). Interested parties can contact the NIH Director's Early Independence Award Program via email at earlyindependence@od.nih.gov for further information. Additional details and application processes are available through the official grants.gov portal.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

7 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
NIH Director's New Innovator Award (DP2 Clinical Trial Optional)The NIH Director's New Innovator Award, managed by the National Institutes of Health under the Department of Health and Human Services, is a forecast opportunity designed to support early-stage investigators. This award focuses on funding exceptionally creative and bold research projects that have the potential to transform scientific fields relevant to the NIH mission. It is part of the broader High-Risk, High-Reward Research Program within the NIH Common Fund and accepts applications across all relevant scientific disciplines. The award is identified as DP2 and notes that clinical trials are optional. Interested parties can contact the NIH Director's New Innovator Award Program via email for further information. This initiative serves as a complement to other NIH programs aimed at supporting the development of early-career researchers pursuing high-impact innovation.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

7 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
NIH Director's Transformative Research Award (R01 Clinical Trial Optional)The NIH Director's Transformative Research Award, managed by the National Institutes of Health under the Department of Health and Human Services, provides funding for individual scientists and research teams engaged in bold and unconventional research. This initiative is part of the NIH Common Fund's High-Risk, High-Reward Research Program and aims to support projects that can establish new scientific paradigms, create transformative technologies, or develop innovative clinical approaches. This specific opportunity is listed as a forecast with a posted date of September 3, 2026, and is categorized as an R01 award where clinical trials are optional. Interested parties can contact the NIH Director's Transformative Research Award Program via email for further information.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

7 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
Innovative Research to Improve Native Hawaiian and Pacific Islander (NHPI) Health Outcomes (R34 - Clinical Trial Optional)The National Institute on Minority Health and Health Disparities within the National Institutes of Health is issuing a forecast for planning grants titled Innovative Research to Improve Native Hawaiian and Pacific Islander (NHPI) Health Outcomes. These grants are designed to support preparatory, feasibility, and pilot activities that advance intervention development or solutions-oriented etiologic studies. A mandatory requirement for all projects is that they must be co-developed with community partners to ensure the effectiveness of the health outcomes being addressed. Priority areas for funding include formative studies on understudied contributors to chronic diseases like cancer and diabetes, as well as the adaptation and pilot-testing of interventions for maternal and infant health. Additionally, the program seeks feasibility and acceptability testing for strategies aimed at reducing behavioral risk factors, such as poor nutrition and smoking, to promote sustained behavior change and measurable improvements in health for NHPI populations.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

16 days ago

DEADLINE

N/A
View Details
NAICS: 334510
Grant
Small Instruments and Modern Equipment for Shared-use Biomedical Research Facilities and Resources (S15 Clinical Trial Not Allowed)The National Institutes of Health, under the Department of Health and Human Services, has issued a forecast for the Small Instruments and Modern Equipment for Shared-use Biomedical Research Facilities and Resources program. This funding opportunity is designed for eligible shared biomedical research facilities, such as core facilities, biorepositories, and model resource facilities, to acquire new small instruments or scientific equipment. The primary objective is to enhance the operational efficiency and capabilities of resources shared by multiple researchers. Priority is given to requests for small instruments utilizing emerging technologies or those that generate physical, chemical, or biomaterial outputs rather than standard digital data. It is important to note that funding is restricted and cannot be used for building-level infrastructure or highly specialized instruments that only indirectly support research. Clinical trials are not allowed under this specific opportunity.
Electromedical and Electrotherapeutic Apparatus Manufacturing

POSTED

17 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Phase 2The National Institutes of Health, through the National Institute on Drug Abuse, is forecasting Phase 2 of the Single Cell Opioid Responses in the Context of HIV (SCORCH) program. This initiative builds upon Phase 1 research by utilizing single-nucleus datasets from human and animal postmortem brain tissue to investigate the interactions between Substance Use Disorder and HIV disease progression within the Central Nervous System. The program aims to employ advanced single cell approaches, including the study of RNA splicing, epigenomic features, and spatial interactions, to conduct both data mining and hypothesis-driven research. The ultimate goal is to enhance the mechanistic understanding of how these conditions affect the brain at subcellular and circuit levels to identify potential targets for novel therapeutic interventions.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

21 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
Translational Research in Maternal and Pediatric Pharmacology and TherapeuticsThe National Institutes of Health, through the Eunice Kennedy Shriver National Institute of Child Health and Human Development, intends to issue a Notice of Funding Opportunity for translational research in maternal and pediatric pharmacology and therapeutics. This initiative aims to improve safe and effective precision therapeutics for pregnant women, lactating women, infants, children, and adolescents. The program focuses on advancing precision medicine via novel tools and technologies, developing safer therapeutics, improving patient-provider communication regarding drug safety, and scaling evidence-based interventions. This forecast is part of the agency's stewardship of the Best Pharmaceuticals for Children Act and recommendations from the Task Force on Research Specific to Pregnant Women and Lactating Women. While the project outlines clear goals for enhancing medication effectiveness and safety across these specific patient populations, applications are not currently being solicited. Interested parties can coordinate with the Obstetric and Pediatric Pharmacology and Therapeutics Branch for further information.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

21 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRC)The Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRC) is a legislatively mandated Centers of Excellence program managed by the National Institutes of Health under the Department of Health and Human Services. This initiative focuses on expanding and intensifying basic, translational, and clinical research regarding muscular dystrophy through interdisciplinary collaboration and shared resources. By supporting innovative center-based projects and providing robust training environments for emerging scientists, the program aims to achieve research outcomes that exceed the capabilities of stand-alone grants. A critical component of the program is its commitment to patient-centered research, actively engaging patient and advocacy communities to increase awareness and ensure that study designs are informed by patient perspectives. This forecast opportunity is supported by several grant authorities, including 42 U.S.C. 281, 283g, 285g, and 284h. Interested parties can coordinate with the NICHD Intellectual and Developmental Disabilities Branch for further information.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

21 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
Multimodal AI to Accelerate Precision Medicine for Type 1 Diabetes (U01- Clinical Trials Not Allowed)The National Institutes of Health, through the National Institute of Diabetes and Digestive and Kidney Diseases, is seeking a coordinated, milestone-driven research project titled Multimodal AI to Accelerate Precision Medicine for Type 1 Diabetes. This initiative aims to integrate large, longitudinal, and multimodal datasets from various T1D research consortia to examine how different biological processes, tissues, and organs interact to drive the development and progression of the disease. By combining human pancreas and clinical data, the project seeks to uncover new insights into T1D biology, identify biomarkers, and inform personalized approaches for prevention and treatment. To achieve these goals, the project will focus on the development and testing of advanced multimodal AI models and AI-enabled research workflows. Key technical objectives include creating new methods for data integration and generating privacy-preserving synthetic datasets. This effort is designed to move beyond the limitations of individual studies to provide a comprehensive understanding of the different forms and stages of Type 1 Diabetes, ultimately accelerating the advancement of precision medicine.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

21 days ago

DEADLINE

N/A
View Details
NAICS: 541714
Grant
Established Clinician Investigator Award to Support Mentoring (KS1)The Established Clinician Investigator Award to Support Mentoring (KS1) is a forecast opportunity issued by the National Institutes of Health under the Department of Health and Human Services. This award is designed to provide established clinician investigators with a sustained period of protected time, enabling them to deliver high-quality mentoring and guidance to early-career clinician research scientists. The program is managed by the Division of Biomedical Research Workforce, which serves as the primary point of contact for interested parties. While specific performance locations and set-aside details are not listed, the award aims to strengthen the pipeline of clinician researchers through structured mentorship support.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

28 days ago

DEADLINE

N/A
View Details

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 650+ contractors already using CLEATUS